HPV vaccination substantially reduced the burden of HPV infection, genital warts, and cervical precancers, especially in highly immunized populations.
The population-level effects of human papillomavirus (HPV) immunization began to emerge 4 years after vaccination programs were introduced. Now, researchers have performed an updated review and meta-analysis of 65 studies measuring the effects of HPV immunization on frequency of HPV infection, genital warts, and cervical intraepithelial neoplasia grade 2+ (CIN2+; a precursor of cervical cancer) 10 years after vaccine implementation in 14 high-income countries.
Prevalence of HPV 16 and 18 (the subtypes that most commonly cause cervical cancer) was reduced by 83% among girls aged 13 to 19 and 66% among women aged 20 to 24. Diagnosis of genital warts fell by 67% (girls aged 13–19), 54% (women aged 20–24), and 31% (women aged 25–29). CIN2+ was r…
Reviewing Author
DisclosuresConsultant/Advisory BoardAicuris; Bayer; GSK; Innovative Molecules; Merck; MAPP Biopharmaceutical (Safety Monitoring Committee)
RoyaltiesUpToDate
Grant/Research SupportNIH/National Institute of Allergy and Infectious Diseases; GSK; Moderna; Assembly Biomedical; Aicuris
Editorial BoardsSexually Transmitted Diseases; Sexually Transmitted Infections; Journal of Infectious Diseases
Leadership PositionsID Division Chiefs Community of Practice (At-Large Member)
DisclosuresConsultant/Advisory BoardAicuris; Bayer; GSK; Innovative Molecules; Merck; MAPP Biopharmaceutical (Safety Monitoring Committee)
RoyaltiesUpToDate
Grant/Research SupportNIH/National Institute of Allergy and Infectious Diseases; GSK; Moderna; Assembly Biomedical; Aicuris
Editorial BoardsSexually Transmitted Diseases; Sexually Transmitted Infections; Journal of Infectious Diseases
Leadership PositionsID Division Chiefs Community of Practice (At-Large Member)